Merck, Moderna claim encouraging melanoma vaccine trial results
Culture Index
Score Breakdown
Relevance
3/25
Freshness
25/25
Authority
18/20
Brand Signal
4/15
Depth
6/15
5-Axis Cultural Radar
US pharmaceutical firms Merck and Moderna announced on Wednesday encouraging results from a trial of their experimental vaccine against melanoma, potentially clearing the way for approval. The vaccine, called intismeran autogene, showed “statistically significant and clinically meaningful improvements” for skin cancer patients when used with Merck’s Keytruda treatment, the companies said in a stat
